Ryvu Therapeutics appoints Justyna Żółtek to management board
Ella Day | May 29, 2025 | Appointment | Medical Communications, Research and Development | Oncology, Ryvu Therapeutics, chief people officer, human resources, management board, oncology
Ryvu Therapeutics has promoted Justyna Żółtek, chief people officer, to its management board. The appointment reflects the company’s focus on organisational development as it continues to advance a pipeline of oncology programmes.
Żółtek joined Ryvu in 2021, leading the creation of its human resources (HR) function during a period of operational growth. Since then, she has developed and implemented the company’s people strategy, built the HR team, and supported talent and leadership development initiatives. Her role has also included managing cultural and structural transitions as Ryvu scaled its R&D operations.
“Justyna has been instrumental in shaping an organisation and culture that supports Ryvu’s scientific and business objectives,” said Piotr Romanowski, president of Ryvu’s supervisory board.
Żółtek brings over 15 years of HR leadership experience across sectors including biotech, energy, construction and technology. She specialises in scaling HR infrastructure and supporting transformation in high-growth companies.
Ryvu is a clinical-stage biotechnology company focused on small molecule and antibody-drug conjugates-based therapies for emerging oncology targets. Its lead programme, RVU120, is currently in phase 2 trials for acute myeloid leukemia, myelodysplastic syndromes and myelofibrosis.
Ella Day
29/5/25
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
